Pfizer O O O O
Inc. O O O O
(NYSE: O O O O
PFE) O O O O
announced O O O O
today O O O O
that O O O O
the O O O O
U.S. O O O O
Food Reason 5 ScientificAuthority O
and Reason 5 ScientificAuthority O
Drug Reason 5 ScientificAuthority O
Administration's Reason 5 ScientificAuthority O
(FDA) Reason 5 ScientificAuthority O
Vaccines Reason 5 ScientificAuthority O
and Reason 5 ScientificAuthority O
Related Reason 5 ScientificAuthority O
Biological Reason 5 ScientificAuthority O
Products Reason 5 ScientificAuthority O
Advisory Reason 5 ScientificAuthority O
Committee Reason 5 ScientificAuthority O
(VRBPAC) Reason 5 ScientificAuthority O
voted Reason 5 O O
that Reason 5 O O
the Reason 5 O O
available Reason 5 O O
data Reason 5 O O
support Reason 5 O O
the Reason 5 O O
efficacy Reason 5 O O
and Reason 5 O O
safety Reason 5 O O
of Reason 5 O O
its Reason 5 O O
unadjuvanted Reason 5 O O
bivalent Reason 5 O O
respiratory Reason 5 O O
syncytial Reason 5 O O
virus Reason 5 O O
(RSV) Reason 5 O O
prefusion Reason 5 O O
F Reason 5 O O
vaccine Reason 5 O O
candidate Reason 5 O O
RSVpreF Reason 5 O O
or Reason 5 O O
PF-06928316. Reason 5 O O
The O O O O
Committee O O O O
voted O O O O
14 O O O O
to O O O O
0 O O O O
on O O O O
effectiveness O O O O
and O O O O
10 O O O O
to O O O O
4 O O O O
on O O O O
safety. O O O O
The O O O O
vaccine O O O O
candidate O O O O
is O O O O
currently O O O O
under O O O O
FDA O O ScientificAuthority O
review O O O O
for O O O O
the O O O O
prevention O O O O
of O O O O
medically O O O O
attended O O O O
lower O O O O
respiratory O O O O
tract O O O O
disease O O O O
(MA-LRTD) O O O O
and O O O O
severe O O O O
MA-LRTD O O O O
caused O O O O
by O O O O
RSV O O O O
in O O O O
infants O O O O
from O O O O
birth O O O O
up O O O O
to O O O O
six O O O O
months O O O O
of O O O O
age O O O O
by O O O O
active O O O O
immunization O O O O
of O O O O
pregnant O O O O
individuals. O O O O
"We Reason 5 O O
are Reason 5 O O
encouraged Reason 5 O O
by Reason 5 O O
the Reason 5 O O
outcome Reason 5 O O
of Reason 5 O O
today's Reason 5 O O
VRBPAC Reason 5 O O
meeting Reason 5 O O
as Reason 5 O O
it Reason 5 O O
is Reason 5 O O
a Reason 5 O O
critical Reason 5 O O
step Reason 5 O O
forward Reason 5 O O
in Reason 5 O O
the Reason 5 O O
scientific Reason 5 O O
community's Reason 5 O O
long-sought-after Reason 5 O O
goal Reason 5 O O
to Reason 5 O O
help Reason 5 O O
prevent Reason 5 O O
RSV Reason 5 O O
disease Reason 5 O O
in Reason 5 O O
infants Reason 5 O O
during Reason 5 O O
their Reason 5 O O
most Reason 5 O O
vulnerable Reason 5 O O
first Reason 5 O O
six Reason 5 O O
months Reason 5 O O
of Reason 5 O O
life," Reason 5 O O
said Reason 5 O O
Annaliesa Reason 5 O O
Anderson, Reason 5 O O
Ph.D., Reason 5 O O
Senior Reason 5 O O
Vice Reason 5 O O
President Reason 5 O O
and Reason 5 O O
Chief Reason 5 O O
Scientific Reason 5 O O
Officer, Reason 5 O O
Vaccine Reason 5 O O
Research Reason 5 O O
and Reason 5 O O
Development, Reason 5 O O
Pfizer. Reason 5 O O
"If Reason 5 O O
approved, Reason 5 O O
our Reason 5 O O
RSV Reason 5 O O
vaccine Reason 5 O O
candidate Reason 5 O O
has Reason 5 O O
the Reason 5 O O
potential Reason 5 O O
to Reason 5 O O
be Reason 5 O O
the Reason 5 O O
first Reason 5 O O
maternal Reason 5 O O
immunization Reason 5 O O
vaccine Reason 5 O O
to Reason 5 O O
help Reason 5 O O
protect Reason 5 O O
infants Reason 5 O O
at Reason 5 O O
first Reason 5 O O
breath Reason 5 O O
through Reason 5 O O
their Reason 5 O O
first Reason 5 O O
six Reason 5 O O
months Reason 5 O O
of Reason 5 O O
life Reason 5 O O
from Reason 5 O O
this Reason 5 O O
potentially Reason 5 O O
serious Reason 5 O O
infection." Reason 5 O O
The O O O O
VRBPAC O O O O
based O O O O
its O O O O
recommendation O O O O
on O O O O
the O O O O
scientific O O O O
evidence O O O O
shared O O O O
by O O O O
Pfizer, O O O O
including O O O O
primary O O O O
analysis O O O O
results O O O O
from O O O O
the O O O O
pivotal O O O O
Phase O O O O
3 O O O O
clinical O O O O
trial O O O O
(NCT04424316) O O O O
MATISSE O O O O
(MATernal O O O O
Immunization O O O O
Study O O O O
for O O O O
Safety O O O O
and O O O O
Efficacy) O O O O
announced O O O O
in O O O O
November O O O O
2022. O O O O
These O O O O
results O O O O
were O O O O
also O O O O
recently O O O O
published O O O O
in O O O O
The O O O O
New O O O O
England O O O O
Journal O O O O
of O O O O
Medicine. O O O O
The O O O O
role O O O O
of O O O O
the O O O O
VRBPAC O O O O
is O O O O
to O O O O
provide O O O O
recommendations O O O O
to O O O O
the O O O O
FDA; O O ScientificAuthority O
however, O O O O
these O O O O
recommendations O O O O
are O O O O
not O O O O
binding. O O O O
The O O O O
FDA's O O O O
decision O O O O
on O O O O
the O O O O
potential O O O O
approval O O O O
of O O O O
RSVpreF O O O O
for O O O O
the O O O O
prevention O O O O
of O O O O
MA-LRTD O O O O
and O O O O
severe O O O O
MA-LRTD O O O O
caused O O O O
by O O O O
RSV O O O O
in O O O O
infants O O O O
by O O O O
active O O O O
immunization O O O O
of O O O O
pregnant O O O O
individuals O O O O
is O O O O
expected O O O O
by O O O O
the O O O O
Prescription O O O O
Drug O O O O
User O O O O
Fee O O O O
Act O O O O
(PDUFA) O O O O
goal O O O O
date O O O O
in O O O O
August O O O O
2023. O O O O
Burden O O O O
of O O O O
RSV O O O O
in O O O O
Infants O O O O
RSV O O O O
is O O O O
a O O O O
contagious O O O O
virus O O O O
and O O O O
a O O O O
common O O O O
cause O O O O
of O O O O
respiratory O O O O
illness.1 O O O O
The Reason 5 O O
virus Reason 5 O O
can Reason 5 O O
affect Reason 5 O O
the Reason 5 O O
lungs Reason 5 O O
and Reason 5 O O
breathing Reason 5 O O
passages Reason 5 O O
of Reason 5 O O
an Reason 5 O O
infected Reason 5 O O
individual Reason 5 O O
and Reason 5 O O
can Reason 5 O O
potentially Reason 5 O O
cause Reason 5 O O
severe Reason 5 O O
illness Reason 5 O O
in Reason 5 O O
young Reason 5 O O
infants, Reason 5 O O
older Reason 5 O O
adults, Reason 5 O O
and Reason 5 O O
individuals Reason 5 O O
with Reason 5 O O
certain Reason 5 O O
chronic Reason 5 O O
medical Reason 5 O O
conditions.2,3,4 Reason 5 O O
In Reason 5 O O
the Reason 5 O O
United Reason 5 O O
States, Reason 5 O O
approximately Reason 5 O O
500,000 Reason 5 O O
to Reason 5 O O
600,000 Reason 5 O O
cases Reason 5 O O
of Reason 5 O O
MA-LRTD Reason 5 O O
due Reason 5 O O
to Reason 5 O O
RSV Reason 5 O O
occur Reason 5 O O
annually Reason 5 O O
in Reason 5 O O
infants Reason 5 O O
less Reason 5 O O
than Reason 5 O O
12 Reason 5 O O
months Reason 5 O O
of Reason 5 O O
age.5 Reason 5 O O
Worldwide, Reason 5 O O
there Reason 5 O O
are Reason 5 O O
an Reason 5 O O
estimated Reason 5 O O
6.6 Reason 5 O O
million Reason 5 O O
cases Reason 5 O O
of Reason 5 O O
RSV Reason 5 O O
annually Reason 5 O O
in Reason 5 O O
infants Reason 5 O O
less Reason 5 O O
than Reason 5 O O
six Reason 5 O O
months Reason 5 O O
of Reason 5 O O
age, Reason 5 O O
with Reason 5 O O
approximately Reason 5 O O
45,000 Reason 5 O O
dying Reason 5 O O
each Reason 5 O O
year Reason 5 O O
from Reason 5 O O
complications Reason 5 O O
associated Reason 5 O O
with Reason 5 O O
the Reason 5 O O
infection, Reason 5 O O
and Reason 5 O O
the Reason 5 O O
vast Reason 5 O O
majority Reason 5 O O
in Reason 5 O O
developing Reason 5 O O
countries.6,7,8 Reason 5 O O
About Reason 5 O O
RSVpreF Reason 5 O O
Pfizer Reason 5 O O
is Reason 5 O O
currently Reason 5 O O
the Reason 5 O O
only Reason 5 O O
company Reason 5 O O
pursuing Reason 5 O O
regulatory Reason 5 O O
applications Reason 5 O O
for Reason 5 O O
an Reason 5 O O
RSV Reason 5 O O
investigational Reason 5 O O
vaccine Reason 5 O O
candidate Reason 5 O O
for Reason 5 O O
both Reason 5 O O
an Reason 5 O O
older Reason 5 O O
adult Reason 5 O O
indication, Reason 5 O O
as Reason 5 O O
well Reason 5 O O
as Reason 5 O O
a Reason 5 O O
maternal Reason 5 O O
indication Reason 5 O O
to Reason 5 O O
help Reason 5 O O
protect Reason 5 O O
infants Reason 5 O O
through Reason 5 O O
maternal Reason 5 O O
immunization. Reason 5 O O
In O O O O
December O O O O
2022, O O O O
Pfizer O O O O
announced O O O O
that O O O O
the O O O O
FDA O O ScientificAuthority O
had O O O O
granted O O O O
priority O O O O
review O O O O
to O O O O
a O O O O
biologics O O O O
license O O O O
application O O O O
for O O O O
RSVpreF O O O O
for O O O O
the O O O O
prevention O O O O
of O O O O
RSV O O O O
disease O O O O
in O O O O
older O O O O
adults O O O O
with O O O O
a O O O O
decision O O O O
on O O O O
whether O O O O
or O O O O
not O O O O
to O O O O
approve O O O O
RSVpreF O O O O
expected O O O O
by O O O O
thePDUFA O O O O
goal O O O O
date O O O O
later O O O O
this O O O O
month. O O O O
This Reason 5 O O
was Reason 5 O O
followed Reason 5 O O
by Reason 5 O O
the Reason 5 O O
February Reason 5 O O
2023 Reason 5 O O
vote Reason 5 O O
by Reason 5 O O
VRBPAC Reason 5 O O
in Reason 5 O O
support Reason 5 O O
of Reason 5 O O
the Reason 5 O O
safety Reason 5 O O
and Reason 5 O O
effectiveness Reason 5 O O
of Reason 5 O O
RSVpreF Reason 5 O O
in Reason 5 O O
adults Reason 5 O O
60 Reason 5 O O
years Reason 5 O O
of Reason 5 O O
age Reason 5 O O
and Reason 5 O O
older. Reason 5 O O
The O O O O
FDA's O O ScientificAuthority O
VRBPAC O O ScientificAuthority O
based O O O O
its O O O O
recommendation O O O O
on O O O O
the O O O O
scientific O O O O
evidence O O O O
shared O O O O
by O O O O
Pfizer, O O O O
including O O O O
interim O O O O
data O O O O
from O O O O
the O O O O
pivotal O O O O
Phase O O O O
3 O O O O
clinical O O O O
trial O O O O
(NCT05035212) O O O O
RENOIR O O O O
(RSV O O O O
vaccine O O O O
Efficacy O O O O
study O O O O
iN O O O O
Older O O O O
adults O O O O
Immunized O O O O
against O O O O
RSV O O O O
disease). O O O O
Top-line O O O O
results O O O O
for O O O O
RENOIR O O O O
were O O O O
previously O O O O
announced O O O O
by O O O O
Pfizer O O O O
in O O O O
August O O O O
2022 O O O O
and O O O O
presented O O O O
at O O O O
IDWeek O O O O
and O O O O
the O O O O
CDC's O O O O
Advisory O O O O
Committee O O O O
on O O O O
Immunization O O O O
Practices O O O O
(ACIP) O O O O
in O O O O
October O O O O
2022, O O O O
as O O O O
well O O O O
as O O O O
recently O O O O
published O O O O
in O O O O
The O O O O
New O O O O
England O O O O
Journal O O O O
of O O O O
